Colli-Pee.
First-void urine, same volume every time.

Colli-Pee captures a fixed, standardised volume of first-void urine (the first-catch fraction richest in urogenital cells and analytes) without a random midstream catch. Curated and supplied on the Humans Nexus platform; DNA Genotek is the manufacturer.

Talk to salesHow it works →
Colli-Pee first-void urine collection device by DNA Genotek, on the Humans Nexus platform
The device

The first-catch fraction,
captured cleanly.

Colli-Pee is an all-in-one first-void urine collector: a diverter directs the very first part of the urine stream into a tube that fills to a defined volume and stops, so every sample is the same standardised first-catch fraction rather than an uncontrolled random catch. The tube can be neat or prefilled with a DNA/analyte-conservation medium that stabilises the sample for ambient transport, and is available across a range of collection volumes. Humans Nexus curates and supplies the device on its platform; DNA Genotek is the legal manufacturer (the device was invented by Novosanis; both are OraSure companies).

Why it matters

The first catch carries the signal.

For urogenital targets, where in the stream you collect changes what you measure. The first-void fraction flushes cells and analytes shed from the urethra and lower genital tract, so it concentrates the signal that a random midstream sample dilutes. Standardising both which fraction and how much is collected is what makes urine a reproducible molecular matrix (the basis for the HPV, STI and biomarker evidence below).

First-void, by designA diverter captures the first-catch fraction every time, not a variable midstream sample.
Defined volumeThe tube fills to a set volume and stops, a standardised input for reproducible molecular results.
Stabilised optionA conservation medium can be prefilled to preserve DNA and analytes for ambient transport.
How it works

Catch. Stabilise. Return.

01Catch

The patient starts urinating into the device; the diverter routes the first-void fraction into the collector.

02Stabilise

The tube fills to its defined volume and, where used, mixes the sample with a conservation medium.

03Seal & return

Cap and drop it in the tracked mailer, chain of custody from the first second.

On the platform

Assembled into a kit.

Colli-Pee is curated onto the platform and assembled into a regulated Humans Nexus collection kit (device, conservation medium where the assay requires it, tamper-evident return packaging and app-guided instructions, under its own UDI).

The deviceColli-Pee first-void collector at the volume the programme requires.
The stabilisationOptional DNA/analyte-conservation medium for ambient transport, plus tamper-evident return packaging.
The guidanceApp-guided instructions for a clean first-void collection at home.

Urine on the platform →

Who it’s for

For urogenital molecular work.

LaboratoriesA standardised first-void matrix for HPV and STI molecular testing
Screening programmesNon-invasive self-sampling to widen cervical-screening reach
Digital healthAt-home STI and urogenital testing behind your app
ResearchersReproducible first-void urine for biomarker and liquid-biopsy work

Good to know.

What does Colli-Pee collect?

A standardised, defined volume of first-void (first-catch) urine (the fraction richest in urogenital cells and analytes) captured by a diverter rather than a random midstream sample.

Why first-void rather than midstream urine?

For urogenital targets such as HPV and STIs, the first-void fraction concentrates the cells and analytes shed from the lower genital tract that a midstream sample dilutes, which is why it is the preferred molecular matrix.

What is its regulatory status?

Colli-Pee is CE-marked, and its stabilised (conservation-medium) configuration is CE-IVD marked, per the manufacturer; some neat, unstabilised configurations are supplied for research use. Device-level regulatory status is held by DNA Genotek; Humans Nexus assembles the regulated kit around it and validates the method per assay before patient-facing reporting.

Who is the manufacturer?

DNA Genotek is the legal manufacturer; the device was invented by Novosanis, and both are OraSure companies. Humans Nexus curates and supplies it on the platform and assembles the kit around it.

The evidence

The research library.

7 papers

Sample type

Collection format

Device

Topic

Access

Impact of first-void urine volume on chlamydia and gonorrhoea positivity ratesHall et al. · Microbiology Spectrum · 2025 · Open accessAcross ~27,000 specimens, moderate over-collection of first-void urine did not meaningfully change chlamydia or gonorrhoea positivity (first-void STI detection is robust to volume variation, provided the early urethral fraction is captured).Open-access full text (PDF)
Colli-Pee
Clinical Performance of the OncoPredict HPV Screening Assay on Self-Collected Vaginal and Urine Specimens (VALHUDES)Giubbi et al. · J. Medical Virology · 2024 · Open accessAn independent VALHUDES evaluation found HPV screening on Colli-Pee first-void urine detected high-grade cervical lesions with sensitivity comparable to clinician-collected cervical samples (reinforcing urine self-sampling for cervical screening).Open-access full text (PDF)
Colli-Pee
Impact of Collection Volume and DNA Extraction Method on the Detection of Biomarkers and HPV DNA in First-Void UrineTéblick et al. · Molecules · 2021 · Open accessIn first-void urine collected with Colli-Pee, the extraction method influenced HPV and human DNA yield more than the collected volume did (standardising processing matters at least as much as standardising volume).Open-access full text (PDF)
Colli-Pee
Clinical and analytical evaluation of high-risk HPV testing on Colli-Pee first-void urine using the VALHUDES protocolVan Keer et al. · Gynecologic Oncology · 2021 · PaywalledHigh-risk HPV testing on first-void urine self-collected with Colli-Pee was about as sensitive (relative sensitivity 0.95) and specific for CIN2+ as clinician-taken cervical samples, supporting standardised first-void urine as a valid screening matrix.
Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void UrinePattyn et al. · Frontiers in Immunology · 2020 · Open accessVaccine-induced HPV antibodies from cervicovaginal secretions can be measured in first-void urine and correlate with serum (demonstrating first-void urine as a non-invasive liquid-biopsy matrix beyond nucleic-acid detection).Open-access full text (PDF)
Colli-Pee
Evaluation of Colli-Pee first-void urine self-sampling at home versus clinic-based collection for sexually transmitted infections in MSMDe Baetselier et al. · BMJ Open · 2019 · Open accessAt-home first-void urine self-collection with Colli-Pee was feasible, well accepted, and gave chlamydia/gonorrhoea detection comparable to routine clinic-based urine (supporting home first-void sampling for populations needing frequent STI testing).Open-access full text (PDF)
Optimization of HPV DNA detection in urine by improving collection, storage, and extractionVorsters et al. · European J. Clinical Microbiology & Infectious Diseases · 2014 · PaywalledCollecting a first-void (not midstream) sample and combining it immediately with a DNA-conservation buffer markedly improves urinary HPV DNA detection (suboptimal collection otherwise underestimates true prevalence).

External links open an open-access full text where one exists, otherwise the publisher or PubMed record. These citations describe the published evidence for the collection formats and devices (not claims about specific Humans Nexus assays, which are validated per analyte and per laboratory).

Put first-void urine on your platform.

Talk to us about Colli-Pee for your HPV, STI or biomarker programme.

Talk to salesUrine on the platform →